Sanjivani Paranteral Ltd
Incorporated in 1994, Sanjivani Parenteral Ltd is a research-based and export-oriented pharmaceutical company[1]
- Market Cap ₹ 264 Cr.
- Current Price ₹ 215
- High / Low ₹ 397 / 200
- Stock P/E 32.5
- Book Value ₹ 32.0
- Dividend Yield 0.23 %
- ROCE 28.5 %
- ROE 24.6 %
- Face Value ₹ 10.0
Pros
Cons
- Promoter holding is low: 31.2%
- Debtor days have increased from 59.2 to 86.8 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|
54.41 | 70.10 | 71.55 | |
46.18 | 59.76 | 60.90 | |
Operating Profit | 8.23 | 10.34 | 10.65 |
OPM % | 15.13% | 14.75% | 14.88% |
0.52 | 1.22 | 1.17 | |
Interest | 0.25 | 0.59 | 0.79 |
Depreciation | 0.93 | 0.62 | 0.65 |
Profit before tax | 7.57 | 10.35 | 10.38 |
Tax % | 18.63% | 21.84% | |
6.17 | 8.09 | 8.12 | |
EPS in Rs | 5.28 | 6.81 | 6.84 |
Dividend Payout % | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 29% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 31% |
Stock Price CAGR | |
---|---|
10 Years: | 21% |
5 Years: | 87% |
3 Years: | 61% |
1 Year: | -29% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 25% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2024 | Mar 2025 | |
---|---|---|
Equity Capital | 11.68 | 11.88 |
Reserves | 16.22 | 26.11 |
0.97 | 8.14 | |
14.53 | 32.07 | |
Total Liabilities | 43.40 | 78.20 |
9.94 | 20.64 | |
CWIP | 0.00 | 19.11 |
Investments | 0.00 | 0.00 |
33.46 | 38.45 | |
Total Assets | 43.40 | 78.20 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2024 | Mar 2025 | |
---|---|---|
-10.70 | 12.40 | |
-12.21 | -21.91 | |
23.16 | 10.46 | |
Net Cash Flow | 0.24 | 0.94 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2024 | Mar 2025 | |
---|---|---|
Debtor Days | 31.53 | 86.85 |
Inventory Days | 124.70 | 94.77 |
Days Payable | 73.56 | 137.51 |
Cash Conversion Cycle | 82.67 | 44.11 |
Working Capital Days | 35.55 | -0.10 |
ROCE % | 28.46% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Dividend Updates
2d - Final dividend 5% (Rs.0.50/share) for FY2024-25 paid on 07 Oct 2025; record date 19 Sep 2025.
-
Closure of Trading Window
29 Sep - Trading window closed from 01-Oct-2025 until 48 hours after Q2 (30-Sep-2025) unaudited results.
-
Announcement under Regulation 30 (LODR)-Change in Management
27 Sep - Ashwani A. Khemka re-appointed MD (1 Aug 2025–31 Jul 2030); HD and Associates appointed secretarial auditor.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 27 Sep
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
26 Sep - 31st AGM on 26 Sep 2025: FY2025 financials adopted, dividend declared, director appointments and secretarial auditor appointed.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Aug 2025Transcript PPT
-
May 2025Transcript PPT
-
Feb 2025Transcript PPT
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Aug 2024TranscriptNotesPPT
-
Jul 2024TranscriptNotesPPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Nov 2023TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Oct 2023TranscriptNotesPPT
-
May 2023TranscriptNotesPPT
-
Mar 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
Business Overview:[1][2]
SPL is a WHO-GMP, DIGEMID, and DDA-certified pharmaceutical company specializing in high-quality parenteral and oral solid formulations. It serves key therapeutic areas including CNS, CVS, antibiotics, urology, anesthetics, gastroenterology, anti-diabetics, anti-fungals, anti-depressants, anti-allergics, muscle relaxants, and vitamin supplements.